Pathology Research International cancer,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 663– 671, 2009. [32] S. Tejpar, M. Peeters, Y. Humblet et al., “Relationship of eﬃcacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer, treated with irinotecan and escalating doses of cetuximab: the EVEREST experience (preliminary data),” Journal of Clinical Oncology, vol. 26, supplement, 2008, abstract no. 4001. [33] E. Van Cutsem, C. H. Ko¨hne, E. Hitre et al., “Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 360, no. 14, pp. 1408–1417, 2009. [34] A. Lie`vre, J. B. Bachet, V. Boige et al., “KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 374–379, 2008. [35] C. S. Karapetis, S. Khambata-Ford, D. J. Jonker et al., “K- ras mutations and beneﬁt from cetuximab in advanced colorectal cancer,” The New England Journal of Medicine, vol. 359, no. 17, pp. 1757–1765, 2008. [36] D. Santini, F. Loupakis, B. Vincenzi et al., “High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice,” Oncologist, vol. 13, no. 12, pp. 1270–1275, 2008. [37] S. Artale, A. Sartore-Bianchi, S. M. Veronese et al., “Muta- tions of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4217–4219, 2008. [38] M. C. Etienne-Grimaldi, J. L. Formento, M. Francoual et al., “K-Ras mutations and treatment outcome in colorectal can- cer patients receiving exclusive ﬂuoropyrimidine therapy,” Clinical Cancer Research, vol. 14, no. 15, pp. 4830–4835, 2008. [39] G. Folprecht, T. Gruenberger, W. O. Bechstein et al., “Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial,” The Lancet Oncology, vol. 11, no. 1, pp. 38–47, 2010. [40] S. E. Baldus, K. L. Schaefer, R. Engers, D. Hartleb, N. H. Stoecklein, and H. E. Gabbert, “Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorec- tal adenocarcinomas and their corresponding metastases,” Clinical Cancer Research, vol. 16, no. 3, pp. 790–799, 2010. [41] A. Mancuso, R. Sollami, F. Recine et al., “Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy,” Journal of Clinical Oncology, vol. 28, no. 36, pp. e756–e758, 2010. [42] E. Van Cutsem, I. Lang, G. Folprecht et al., “Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the inﬂuence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial,” in Proceedings of the Gastrointestinal Cancers Symposium, Orlando, Fla, USA, January 2010, abstract no. 281. [43] C. Bokemeyer, I. Bondarenko, J. T. Hartmann et al., “Biomarkers predictive for outcome in patients with metastatic colorectal cancer treated with ﬁrst-line FOLFOX4 plus or minus cetuximab: updated data from the OPUS study,” in Proceedings of the ASCO Gastrointestinal Cancers Symposium, Orlando, Fla, USA, January 2010, abstract no. 428. [44] S. Siena, J. Cassidy, J. Tabernero et al., “Randomized phase III study of panitumumab with FOLFOX4 compared to FOL- FOX4 alone as ﬁrst-line treatment for metastatic colorectal cancer: PRIME trial,” in Proceedings of the Gastrointestinal 9 Cancers Symposium, Orlando, Fla, USA, January 2010, abstract no. 283. [45] C. Kohne, K. Mineur, R. Greil et al., “Primary analysis of a phase II study (20060314) combining ﬁrst-line panitu- mumab with FOLFIRI in the treatment of patients with metastatic colorectal cancer,” in Proceedings of the Gastroin- testinal Cancers Symposium, Orlando, Fla, USA, January 2010, abstract no. 414. [46] J. Hecht, E. Mitchell, J. Baranda et al., “Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1–9%) or negative (<1%) levels of epidermal growth receptor (EGFr),” Journal of Clinical Oncology, vol. 24, supplement, 2006, abstract no. 3506. [47] F. Di Fiore, F. Blanchard, F. Charbonnier et al., “Clinical relevance of KRAS mutation detection in metastatic colorec- tal cancer treated by Cetuximab plus chemotherapy,” British Journal of Cancer, vol. 96, no. 8, pp. 1166–1169, 2007. [48] S. Benvenuti, A. Sartore-Bianchi, F. Di Nicolantonio et al., “Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti- epidermal growth factor receptor antibody therapies,” Cancer Research, vol. 67, no. 6, pp. 2643–2648, 2007. [49] J. Tol, M. Koopman, A. Cats et al., “Chemotherapy, beva- cizumab, and cetuximab in metastatic colorectal cancer,” The New England Journal of Medicine, vol. 360, pp. 563–572, 2009. [50] J. R. Hecht, E. Mitchell, T. Chidiac et al., “A randomized phase IIIB trial of chemotherapy, bevacizumab, and pani- tumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 5, pp. 672–680, 2009. [51] H. Linardou, I. J. Dahabreh, D. Kanaloupiti et al., “Assess- ment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer,” The Lancet Oncology, vol. 9, no. 10, pp. 962–972, 2008. [52] J. L. Bos, E. R. Fearon, S. R. Hamilton et al., “Prevalence of ras gene mutations in human colorectal cancers,” Nature, vol. 327, no. 6120, pp. 293–297, 1987. [53] B. Vogelstein, E. R. Fearon, S. R. Hamilton et al., “Genetic alterations during colorectal-tumor development,” The New England Journal of Medicine, vol. 319, no. 9, pp. 525–532, 1988. [54] D. Lambrechts, W. De Roock, H. Prenen et al., “The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 15, supplement, 2009, abstract no. 4020. [55] N. Irahara, Y. Baba, K. Nosho et al., “NRAS mutations are rare in colorectal cancer,” Diagnostic Molecular Pathology, vol. 19, no. 3, pp. 157–163, 2010. [56] H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. [57] J. Tol, I. D. Nagtegaal, and C. J. A. Punt, “BRAF mutation in metastatic colorectal cancer,” The New England Journal of Medicine, vol. 361, no. 1, pp. 98–99, 2009. [58] S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli, “Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer,” Journal of the National Cancer Institute, vol. 101, no. 19, pp. 1308–1324, 2009.